Double-expressor Lymphoma (DEL) (DBCOND0118159)

Identifiers

Synonyms

Double-Expressor Lymphoma / Double Expressor Lymphoma / Diffuse large B-cell lymphomas / Diffuse large B-cell lymphoma NOS / Diffuse non-Hodgkin's lymphoma, large cell (disorder) / Lymphoma, Large B-Cell, Diffuse / Diffuse large B-cell lymphoma / Anaplastic diffuse large B-cell lymphoma / Malignant lymphoma, large B-cell, diffuse (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05600686	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma	Beta-D-Glucose Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Loncastuximab tesirine Prednisone Rituximab Vincristine	treatment	2	recruiting
NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Prednisone Rituximab Sulfate ion Venetoclax Vincristine	treatment	2 / 3	active_not_recruiting
NCT04164368	Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients	Cyclophosphamide Doxorubicin Lenalidomide Prednisone Rituximab Vincristine	treatment	2	completed
NCT04479267	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma	Cyclophosphamide Doxorubicin Methylprednisolone Polatuzumab vedotin Prednisolone Prednisone Rituximab	treatment	2	recruiting
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	Fimepinostat Rituximab Venetoclax	treatment	1	completed